Marcus Jewell, an officer of Cellebrite DI Ltd., filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 31,728 ordinary shares on NASDAQ scheduled for November 16, 2026.

Key Highlights

  • Proposed sale: Marcus Jewell, listed as an officer of Cellebrite DI Ltd., intends to sell 31,728 ordinary shares with an aggregate market value of $402,945.60.
  • Source of shares: The shares were acquired on November 15, 2026, through restricted share units that vested under an issuer S-8 registered plan, classified as employee compensation.
  • Sell-to-cover arrangement: According to the filing, the sale is pursuant to "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only."
  • Shares outstanding: The filing states 251,341,060 ordinary shares outstanding at the time of notice.
  • Prior sales in past 3 months: The filing discloses two prior sales: 411 shares on August 12, 2026, with gross proceeds of $6,603.86, and 12,562 shares on August 21, 2026, with gross proceeds of $141,216.97.
  • Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Jewell's RSU Vesting and Planned Tax-Related Share Sale at Cellebrite

Cellebrite DI Ltd. (NASDAQ:CLBT), an Israel-based company headquartered at 94 Shlomo Shmelzer Road, Petah Tikva, is the issuer in this Form 144 notice. The filing identifies Marcus Jewell as an officer of the company and discloses his intent to sell 31,728 ordinary shares, par value NIS 0.00001, on or around November 16, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

According to the filing, the shares to be sold were acquired on November 15, 2026, the day before the planned sale, as restricted share units vested under an issuer S-8 registered plan. The nature of payment is described as employee compensation. The filing states that the transaction is "a mandatory, non-discretionary, sell-to-cover arrangement for the purposes of satisfying income tax liabilities incurred upon vesting of restricted share unit awards only," reflecting that the sale is not at Jewell's discretion but is instead structured to cover tax obligations arising from the vesting event.

The filing also discloses Jewell's sales of Cellebrite common shares over the prior three months. On August 12, 2026, he sold 411 shares for gross proceeds of $6,603.86. On August 21, 2026, he sold 12,562 shares for gross proceeds of $141,216.97. These figures are provided as required by Rule 144's aggregation disclosure requirements. The notice was signed by Marcus Jewell and dated November 10, 2026.

What Was Disclosed

Cellebrite DI Ltd. officer Marcus Jewell filed a Form 144 on November 10, 2026, noticing a proposed sale of 31,728 ordinary shares on November 16, 2026, valued at $402,945.60, acquired via RSU vesting and designated for a mandatory sell-to-cover tax arrangement.